Merck KGaA Moves MS Hopeful Evobrutinib To Phase III, Plans Pipeline Update
Merck KGaA said its second-quarter performance was boosted by its Life Science lab unit and milestone payments from drug development partners and promised analysts a pipeline update next month.
You may also be interested in...
The German group believes its €2bn target of pipeline sales by 2022 is achievable. It is hoping for a healthy contribution from rare lung cancer drug tepotinib.
The German company is predicting sales in mid-triple-digits in 2019 for Mavenclad, its multiple sclerosis drug which has just been launched in the US, and has highlighted more promising MS data for its BTK inhibitor evobrutinib.
Already working with Pfizer on the immunotherapy Bavencio, Merck KGaA has bagged another big pharma player in GSK to progress what has been heralded by analysts as the German group's oncology game changer, M7824, which combines two powerful and synergistic anticancer mechanisms into one molecule.